GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents

Core Points - GENFIT, a biopharmaceutical company focused on rare and life-threatening liver diseases, announced its Combined Shareholders Meeting scheduled for June 17, 2025 [1] - The meeting will be held at the Faculty of Pharmaceutical Sciences in Lille, France, and will be accessible via live broadcast on the company's website [3] - Shareholders will have the option to vote online through the VOTACCESS platform, with a tutorial provided for guidance [4] Company Overview - GENFIT is a late-stage biopharmaceutical company with over two decades of experience in liver disease research and development [5] - The company has a diversified R&D portfolio, focusing on Acute-on-Chronic Liver Failure (ACLF) and other serious diseases, with five assets under development in its ACLF franchise [5] - GENFIT's expertise includes the accelerated approval of its drug Iqirvo® (elafibranor) for Primary Biliary Cholangitis (PBC) by major regulatory authorities [5] - The company also has a diagnostic franchise targeting metabolic dysfunction-associated steatohepatitis (MASH) and blood ammonia levels [5] - GENFIT is headquartered in Lille, France, with additional offices in Paris, Zurich, and Cambridge, MA, and is listed on both Nasdaq and Euronext [5]